Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis: Editorial

Clinical and Experimental Rheumatology

Volumn 16, Issue 6, 1998, Pages 662-666

  Ferraccioli, G F ^a   Bartoli, E ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CD40 ANTIGEN; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; GOLD SALT; METALLOPROTEINASE; METHOTREXATE; OKT 4; PACLITAXEL; PENICILLAMINE; RAPAMYCIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; XENOBIOTIC AGENT;

DISEASE SEVERITY; DRUG EFFICACY; DRUG MIXTURE; EDITORIAL; HUMAN; INFLAMMATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; XENOBIOTICS;

EID: 0031732549     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (57)